Medication info

Sebika HCT Tablet 10/40/25 Milligrams

Prescription medicationExpired
Ingredient · strength
Olmesartan Medoxomil›Strength being verifiedAmlodipine Besylate›Strength being verifiedHydrochlorothiazide›Strength being verified
Manufacturer / importer
Daiichi Sankyo Korea Co., Ltd.
Appearance
Grayish-red oval film-coated tablet
Packaging
Manufacturer packing unit
Approval status
Expired

MFDS item code 201206781 · Approved 2012.09.13

This product's status changed to Expired on 2023.09.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension
Who uses it
Adults · Children
Adult dosage
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg 5/40/0mg → 5/40/12.5mg → 5/40/25mg 10/40/0mg → 10/40/12.5mg → 10/40/25mg ○ Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ○ Patients with hepatic impairment Use caution when administering to patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine must not be administered to patients with severe hepatic impairment. ○ Elderly patients (65 years of age and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. In particular, experience with this medicine in patients 75 years of age and older is very limited, so they should be monitored very carefully when this medicine is administered.
Children's dosage
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Importer
Daiichi Sankyo Korea Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

Amlodipine and Olmesartan Medoxomil are used to treat essential hypertension, which is high blood pressure of unknown cause. These medications lower blood pressure through different mechanisms, reducing the burden on the cardiovascular system. Amlodipine dilates blood vessels to lower blood pressure, while Olmesartan Medoxomil blocks hormonal actions that raise blood pressure. When used in combination, they can effectively manage blood pressure even in cases where monotherapy is insufficient, helping to reduce risks of heart disease or stroke. Therefore, combination therapy improves blood pressure control in essential hypertension.

Dosage and Administration

Adult dosage

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg 5/40/0mg → 5/40/12.5mg → 5/40/25mg 10/40/0mg → 10/40/12.5mg → 10/40/25mg ○ Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ○ Patients with hepatic impairment Use caution when administering to patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine must not be administered to patients with severe hepatic impairment. ○ Elderly patients (65 years of age and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. In particular, experience with this medicine in patients 75 years of age and older is very limited, so they should be monitored very carefully when this medicine is administered.

Children's dosage

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. This drug should not be used in patients with allergies to the ingredients or similar drugs, pregnant or breastfeeding women, patients with severe hypotension, or those with major issues concerning the heart, kidneys, or liver. Patients with reduced blood volume, impaired kidney function, or liver disease should be especially cautious when using this medication, as it may cause side effects such as hypotension or worsening kidney function, so their condition should be monitored closely. This drug can lower blood pressure, which may cause dizziness or lightheadedness, so caution is required when driving or operating hazardous machinery. During treatment with this drug, regular blood tests to monitor electrolyte levels and kidney function are important, as there is a risk of potassium levels becoming too high or too low. Some patients may experience side effects such as skin allergies, indigestion, headaches, swelling, fatigue, etc., and in rare cases, serious allergic reactions or liver function abnormalities have been reported. Particularly, the skin may become sensitive to sunlight; therefore, prolonged exposure to sunlight should be avoided, and any adverse reactions should be reported to a physician immediately. This drug may interact with other antihypertensive medications, diuretics, or non-steroidal anti-inflammatory drugs, so if other medications are being taken, it is essential to inform the doctor or pharmacist. Women who are pregnant or planning to become pregnant should avoid this medication, and nursing women should also avoid use or consult a specialist. Safety and efficacy in children under 18 have not been established, so administration to this age group is not recommended. Overdosage may result in severe hypotension or arrhythmias; therefore, seek immediate medical attention for appropriate treatment. This drug should be stored in a place protected from moisture, heat, and direct sunlight, out of reach of children, and it is advised not to change the storage container.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimuli, anxiety, mood changes, sleep disturbances, dizziness, orthostatic dizziness, syncope, taste disturbances, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, syncope, convulsions, loss of appetite, tremor, vision changes, reduced tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bloating, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus-like skin reactions, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, pollakiuria, acute renal failure, hematuria, voiding dysfunction, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, drug hypersensitivity, upper abdominal pain, decreased libido, labial edema, lethargy, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, acute respiratory distress syndrome (ARDS)

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Grayish-red oval film-coated tablet

Package unit

Manufacturer packing unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.